Related Experiment Video

Updated: Jun 15, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

United virus: the oncolytic tag-team against cancer!

Fabrice Le Boeuf1, John C Bell

  • 1Ottawa Hospital Research Institute, Ottawa, Ontario, Canada K1H 8L6.

Cytokine & Growth Factor Reviews
|March 16, 2010
PubMed

Insights

Innovative oncolytic virotherapy, using complementary viruses like vaccinia and vesicular stomatitis, offers new hope for aggressive metastatic cancers. Combining these viruses may yield greater therapeutic synergy than current approaches.

Area of Science:

  • Oncology
  • Virology
  • Cancer Therapeutics

Background:

  • Metastatic cancers often resist standard treatments, necessitating novel therapeutic strategies.
  • Oncolytic virotherapy shows promise in clinical trials, with approvals anticipated.
  • Current research explores oncolytic virus combinations with small molecules.

Purpose of the Study:

  • To review rational chemical and biological combination strategies for enhancing oncolytic virotherapy.
  • To highlight the potential of combining vaccinia and vesicular stomatitis oncolytic viruses.

Main Methods:

  • Literature review of existing and proposed combination strategies for oncolytic virotherapy.
  • Analysis of synergistic potential between different oncolytic viruses.

Main Results:

  • Oncolytic virotherapy demonstrates significant effects on cancer progression in human trials.
  • Complementary virus combinations may offer greater therapeutic synergy than virus-small molecule combinations.

Conclusions:

  • Rational design of complementary oncolytic virus therapeutics can enhance treatment efficacy.
  • Combining vaccinia and vesicular stomatitis viruses presents a promising strategy for aggressive cancers.

More Related Videos

Ex Vivo Infection of Live Tissue with Oncolytic Viruses12:08

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Published on: June 25, 2011

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...